Pulmonary Arterial Hypertension Formulary Central

PAHFormulary Central

Sponsored Content

Manuscripts/Supplements

Accessing Pulmonary Arterial Hypertension (PAH) Medication - It Takes a Village!
Accessing Pulmonary Arterial Hypertension (PAH) Medication - It Takes a Village!
Treatment Patterns, Healthcare Resource Utilization, and Healthcare Costs among Patients with Pulmonary Arterial Hypertension in a Real-World US Database
Treatment Patterns, Healthcare Resource Utilization, and Healthcare Costs among Patients with Pulmonary Arterial Hypertension in a Real-World US Database
Using Real World Evidence to Describe PAH Treatment Patterns, Healthcare Resource Utilization, and Costs Associated with PDE-5 Inhibitor Monotherapy
Using Real World Evidence to Describe Pulmonary Arterial Hypertension Treatment Patterns, Healthcare Resource Utilization, and Costs Associated with PDE-5 Inhibitor Monotherapy
Healthcare Resource Utilization and Costs for Patients with Pulmonary Arterial Hypertension: Real-world Documentation of Functional Class
Healthcare Resource Utilization and Costs for Patients with Pulmonary Arterial Hypertension: Real-world Documentation of Functional Class
Prostacyclin Use Among Patients with Pulmonary Arterial Hypertension in the United States: A Retrospective Analysis of a Large Health Care Claims Database
Prostacyclin Use Among Patients with Pulmonary Arterial Hypertension in the United States: A Retrospective Analysis of a Large Health Care Claims Database
Combination Therapy in Pulmonary Arterial Hypertension (PAH): What We Know and What We Do Not Know
Combination Therapy in Pulmonary Arterial Hypertension (PAH): What We Know and What We Do Not Know

Abstracts & Posters

Baseline Demographics and Clinical Characteristics of Chronic Thromboembolic Pulmonary Hypertension Patients in the US Medicare Population
Baseline Demographics and Clinical Characteristics of Chronic Thromboembolic Pulmonary Hypertension Patients in the US Medicare Population
Multiparameter Risk Assessment Tools Applied to the Functional Class (FC II) Cohort from the EARLY (AC-052364) Clinical Trial
Multiparameter Risk Assessment Tools Applied to the Functional Class (FC II) Cohort from the EARLY (AC-052364) Clinical Trial
Comparative Effectiveness of Oral Prostacyclin Pathway Medications on Hospitalization Among Patients with PH: A Retrospective Administrative Claims Study in a US Managed Care Population
Comparative Effectiveness of Oral Prostacyclin Pathway Medications on Hospitalization Among Patients with PH: A Retrospective Administrative Claims Study in a US Managed Care Population
Healthcare Costs and Resource Utilization Prior to Initiation of a Prostacylcin Receptor Agonist for Pulmonary Arterial Hypertension in a Real-world Database Representing a Large US Health Plan
Healthcare Costs and Resource Utilization Prior to Initiation of a Prostacylcin Receptor Agonist for Pulmonary Arterial Hypertension in a Real-world Database Representing a Large US Health Plan
Characterizing Patients Treated with Macitentan for Pulmonary Arterial Hypertension (PAH) in the US Opsumit User Registry (OPUS)
Characterizing Patients Treated with Macitentan for Pulmonary Arterial Hypertension (PAH) in the US Opsumit User Registry (OPUS)
Treatment Patterns Prior to Initiation of a Prostacyclin Receptor Agonist for Pulmonary Arterial Hypertension in a Real-world Database Representing a Large US Health Plan
Treatment Patterns Prior to Initiation of a Prostacyclin Receptor Agonist for Pulmonary Arterial Hypertension in a Real-world Database Representing a Large US Health Plan
Medication Adherence and Risk of Hospitalization in PAH Patients Treated with ERAS or PDE-5IS
Medication Adherence and Risk of Hospitalization in Pulmonary Arterial Hypertension (PAH) Patients Treated with Endothelin Receptor Antagonists (ERAS) or Phosphodiesterase Type 5 Inhibitors (PDE-5IS)
Medication Adherence and Risk of Hospitalization in Pulmonary Arterial Hypertension (PAH) Patients Treated with Endothelin Receptor Antagonists (ERAS) or Phosphodiesterase Type 5 Inhibitors (PDE5IS)
Medication Adherence and Risk of Hospitalization in Pulmonary Arterial Hypertension (PAH) Patients Treated with Endothelin Receptor Antagonists (ERAS) or Phosphodiesterase Type 5 Inhibitors (PDE5IS)
Healthcare Utilization and Costs in Pulmonary Arterial Hypertension (PAH) Patients Treated with Endothelin Receptor Antagonists (ERAS) or Phosphodiesterase Type 5 Inhibitors (PDE-5Is)
Healthcare Utilization and Costs in Pulmonary Arterial Hypertension (PAH) Patients Treated with Endothelin Receptor Antagonists (ERAS) or Phosphodiesterase Type 5 Inhibitors (PDE-5Is)
Treatment Patterns and Medication Adherence and Persistence Among Patients with Pulmonary Arterial Hypertension in a Real-World Database Representing a Large US Health Plan
Treatment Patterns and Medication Adherence and Persistence Among Patients with Pulmonary Arterial Hypertension in a Real-World Database Representing a Large US Health Plan
Comparing PAH-related Hospitalizations Between Hypothetical Commercial and Medicare Patients Using a Decision Tree Model
Comparing PAH-related Hospitalizations Between Hypothetical Commercial and Medicare Patients Using a Decision Tree Model
Decreasing Length of Stay and Pulmonary Arterial Hypertension Related Hospitalizations with Macitentan Using a Decision Tree Model in a Medicare Population
Decreasing Length of Stay and Pulmonary Arterial Hypertension Related Hospitalizations with Macitentan Using a Decision Tree Model in a Medicare Population
Characteristics of Patients Treated for Pulmonary Arterial Hypertension in a Real-World Database Representing a Large US Health Plan
Characteristics of Patients Treated for Pulmonary Arterial Hypertension in a Real-World Database Representing a Large US Health Plan
Reducing Pulmonary Arterial Hypertension-Related Hospitalizations and Length of Stay with Macitentan Using a Decision Tree Model
Reducing Pulmonary Arterial Hypertension-Related Hospitalizations and Length of Stay with Macitentan Using a Decision Tree Model

AJMC Educational Materials

Supplement | Considerations for Optimal Management of Patients With Pulmonary Arterial Hypertension: A Multi-Stakeholder Roundtable Discussion
Supplement | Considerations for Optimal Management of Patients With Pulmonary Arterial Hypertension: A Multi-Stakeholder Roundtable Discussion
Supplement | The Evolution of Prostacyclins in Pulmonary Arterial Hypertension: From Classical Treatment to Modern Management
Supplement | The Evolution of Prostacyclins in Pulmonary Arterial Hypertension: From Classical Treatment to Modern Management
Supplement | Characterizing Pulmonary Hypertension–Related Hospitalization Costs Among Medicare Advantage or Commercially Insured Patients With Pulmonary Arterial Hypertension: A Retrospective Database Study
Supplement | Characterizing Pulmonary Hypertension–Related Hospitalization Costs Among Medicare Advantage or Commercially Insured Patients With Pulmonary Arterial Hypertension: A Retrospective Database Study
Supplement | Combination Therapy in Pulmonary Arterial Hypertension: Is This the New Standard of Care?
Supplement | Combination Therapy in Pulmonary Arterial Hypertension: Is This the New Standard of Care?
Supplement | Pulmonary Arterial Hypertension: Progress and Challenges in the Modern Treatment Era
Supplement | Pulmonary Arterial Hypertension: Progress and Challenges in the Modern Treatment Era
Supplement | Clinical Trial Designs in PAH: Shifting From Functional Measurements to Long-term Clinical Outcomes
Supplement | Clinical Trial Designs in PAH: Shifting From Functional Measurements to Long-term Clinical Outcomes

Archive

Characteristics of Patients, Treatment Patterns and Medication Adherence and Persistence among Patients with Pulmonary Arterial Hypertension in a Large US Health Plan
Pulmonary Arterial Hypertension (PAH) Episodes of Care: Survival Analysis of PAH Patients Based on World Health Organization (WHO) Functional Class (FC)
Minimizing Burden of Disease-Related Hospitalization Among Pulmonary Arterial Hypertension Patients
Treatment Patterns Among Patients Prescribed Pde-5 Inhibitor Monotherapy For Pulmonary Arterial Hypertension
The Patterns of Healthcare Utilization and Prevalence of Pulmonary Arterial Hypertension Patients on Prostacyclin Therapy in the United States
Characteristics of Patients Treated for Pulmonary Arterial Hypertension in a Real-World Database Representing a Large US Health Plan
This page is brought to you by Actelion

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo